Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Scimago
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • MIAR
  • Scientific Indexing Services (SIS)
  • Euro Pub
  • Google Scholar
Share This Page
Journal Flyer
Flyer image
Development, characterization and site specific peptide conjugated PLGA-PEG polymeric nanoparticles with cancer specific active dual targeting delivery system
Nanotechnology Congress & Expo
August 11-13, 2015 Frankfurt, Germany

Madhu Gupta and S P Vyas

Poster-Accepted Abstracts: J Nanomed Nanotechnol

Abstract:

Certain tumor cells over express a membrane-spanning molecule, aminopeptidase N (CD13) isoform, which is the receptor for peptides containing the NGR motif. NGR-modified docetaxel (DTX)-loaded PEG-b-PLGA polymeric nanoparticles (NGR?NPDTX) were developed and evaluated for their in vitro potential in HT-1080 cell line. The NGR?NP-DTX containing particles were about 148 nm in diameter with spherical shape and high encapsulation efficiency. Cellular uptake was confirmed both qualitatively and quantitatively by confocal laser scanning microscopy (CLSM) and flow cytometry. Both quantitatively and qualitatively results confirmed the NGR conjugated nanoparticles revealed the higher uptake of nanoparticles by CD13-overexpressed tumor cells. Free NGR inhibited the cellular uptake of NGR?NP-DTX, revealing the mechanism of receptor mediated endocytosis. In vitro cytotoxicity studies demonstrated that NGR?NP-DTX formulation was more cytotoxic than unconjugated one, which were consistent well with the observation of cellular uptake. Hence, the selective delivery of NGR-NP-DTX formulation in CD13-overexpressing tumors represents a potential approach for the design of nanocarrier-based dual targeted delivery systems for targeting the tumor cells and vasculature.